English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17333/19639 (88%)
Visitors : 5392044      Online Users : 421
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32540


    標題: The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials
    作者: Chih-Wei Chen(陳志偉)
    Chang, Shen-Peng
    Huang, Hui-Ting
    Tang, Hung-Jen
    Lai, Chih-Cheng
    貢獻者: Chi Mei Med Ctr, Div Neurosurg, Dept Surg
    Chia Nan Univ Pharm & Sci, Dept Occupat Safety & Hlth, Inst Ind Safety & Disaster Prevent, Coll Sustainable Environm
    Chi Mei Med Ctr, Dept Pharm
    China Med Univ, Sch Pharm
    Chi Mei Med Ctr, Dept Med
    Chi Mei Med Ctr, Dept Intens Care Med
    關鍵字: ceftaroline
    acute bacterial infection
    pediatric
    community-acquired pneumonia
    skin and skin structure infection
    日期: 2019
    上傳時間: 2020-07-29 13:49:06 (UTC+8)
    出版者: DOVE MEDICAL PRESS LTD
    摘要: Objectives: This meta-analysis aims to assess the clinical efficacy and safety of ceftaroline in treating acute bacterial infections - community-acquired pneumonia (CAP) and skin and skin structure infection (SSSI) in pediatric patients. Methods: The Pubmed, Embase, ClinicalTrials. gov. and the Cochrane databases were searched up to December 31, 2018. Only randomized controlled trials (RCTs) evaluating ceftaroline and other comparators in the treatment of acute bacterial infection in pediatric patients were included. The primary outcome was the clinical cure rate and the secondary outcome was the risk of adverse event. Results: Three RCTs were included. Overall, ceftaroline had a clinical cure rate at end of therapy (EOT) and test of cure (TOC) similar to comparators in the treatment of acute bacterial infection (at EOT, OR, 1.93; 95% CI, 0.88-4.25, I-2= 0%, and at TOC, OR, 1.36; 95% CI, 0.64-2.91, I-2= 14%). In addition, ceftaroline had a clinical failure rate at EOT and TOC similar to comparators in the treatment of acute bacterial infection (at EOT, OR, 0.62; 95% CI, 0.22-1.76, I-2= 0%, and at TOC, OR, 0.68; 95% CI, 0.24-1.91, I-2= 0%). No significant differences were found for the risk of treatment-emergent adverse events (TEAE) in all and different degrees between ceftaroline and comparators (OR, 0.81; 95% CI, 0.37-1.78, I2= 56%). The risks of TEAE and severe adverse events related to study drug were similar between ceftaroline and comparators (TEAE related to study drug, OR, 0.98; 95% CI, 0.52-1.82, I-2= 0%, severe adverse event related to study drug, OR, 1.09; 95% CI, 0.22-5.44, I2= 22%). Conclusions: The clinical efficacy of ceftaroline is as good as comparator therapy in the treatment of acute bacterial infections - CAP and SSSI, and this antibiotic is well tolerated as the comparators.
    關聯: Infection and Drug Resistance, v.12, 1303-1310
    Appears in Collections:[職業安全衛生系(含防災所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.2147-IDR.S199978.pdf1560KbAdobe PDF7View/Open
    index.html0KbHTML27View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback